We are live on ! Find out more
CRMD icon

CorMedix

91 hedge funds and large institutions have $73.3M invested in CorMedix in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 34 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $71.4M → $73.3M (+$1.86M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3.22% less ownership

Funds ownership: 34.65%31.43% (-3.2%)

10% less funds holding

Funds holding: 10191 (-10)

32% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 34

56% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 18

59% less call options, than puts

Call options by funds: $746K | Put options by funds: $1.82M

Holders
91
Holders Change
-10
Holders Change %
-9.9%
% of All Funds
1.31%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
8
Increased
23
Reduced
34
Closed
18
Calls
$746K
Puts
$1.82M
Net Calls
-$1.07M
Net Calls Change
-$120K

CRMD Hedge Fund Activity: Q1 2024 in Review

91 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q1 2024, worth a combined $73.3M — up 2.6% from $71.4M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CRMD and 8 opened new positions — a net loss of 10 holders — while 34 trimmed existing stakes and 23 added.

The largest buyer was Vanguard Group, adding an estimated $357K. The largest seller was Marshall Wace, cutting an estimated $1.35M.

  • 91 institutional investors held CorMedix (CRMD) as of Q1 2024, down from 101 in Q4 2023.
  • Funds reported $73.3M of CorMedix stock for Q1 2024, up 2.6% quarter-over-quarter.
  • 8 funds opened new CorMedix positions in Q1 2024 and 18 closed out, a net change of -10 holders.
  • The largest CorMedix buyer in Q1 2024 was Vanguard Group, an estimated $357K added.
  • The largest CorMedix seller in Q1 2024 was Marshall Wace, an estimated $1.35M sold.

Based on aggregated 13F filings for Q1 2024.